-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
In Brief for November 13, 2024
US FDA approves TTFields therapy as a treatment for mNSCLC.
-
Climate Change, Pollution, War, and More Increasing Risk, Impacting Management of Lung Cancer Worldwide
Dr. Leticia Nogueira and other experts explored non-tobacco factors that are playing a role in our evolving knowledge during a WCLC 24 plenary session.
-
Artificial Intelligence-Powered Tools May Help Develop Predictive Biomarkers
Dr. Kenneth O’Byrne says research shows novel method for analyzing tissue samples may help predict immunotherapy response.
-
Interim Analysis Shows IDeate-Lung01 Study Met Primary Endpoint
Dr. Charles Rudin says early data look promising for I-DXd in patients with ES-SCLC.
-
Hands-On Genomics Workshop Enables Participants to Integrate Genomic Testing Into Patient Care
Drs. Ramaswamy Govindan, Richard Haspel, and Aparna Sharma took the audience on a guided tour of pragmatic lung cancer genomics.
-
Save the Date: Planning Begins for the 2025 World Conference on Lung Cancer
Drs. Isabelle Opitz, Umberto Malapelle, Noemi Reguart, and Jarushka Naidoo will co-chair the event, which will return to Barcelona next September.
-
In Brief for October 23, 2024
Pembrolizumab, amivantamab-vmjw, osimertinib, and nivolumab join the list of FDA-approved treatments for various lung cancer indications.
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
During the session, Dr. Hisao Asamura reviewed the criteria changes in the new 9th edition of the TNM classification recommendations.
-
Novel, Targeted TKI Brings Hope to a Rare, Clinically Challenging Disease
Dr. Gerrina Ruiter says zongertinib shows encouraging preliminary findings in patients with HER2-mutated NSCLC.
-
Study Results Support Continued Research of HER2-Targeted TKI
Dr. Xiuning Le presented data from a first-in-human trial that show a rapid, durable response in HER2-mutated NSCLC.